Evidence map›Paper›PMID 41151835›Full record

ArticleJournal for immunotherapy of cancer2025

Bi-specific T cell-engaging antibody triggers protective immune memory and glioma microenvironment remodeling in immune-competent preclinical models.

Markella Zannikou, Joseph T Duffy, Daniele Procissi, Hinda Najem, Rebecca N Levine, Aditi Thakur, Dolores Hambardzumyan, Catalina Lee-Chang, Lara Leoni, Craig M Horbinski and 5 more

Abstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Markella Zannikou *Department of Neurological Surgery, Northwestern University, Chicago, IL, USA.
Joseph T Duffy *Department of Neurological Surgery, Northwestern University, Chicago, IL, USA.
Daniele ProcissiDeparment of Radiology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Hinda NajemDepartment of Neurological Surgery, Northwestern University, Chicago, IL, USA.
Rebecca N LevineDepartment of Neurological Surgery, Northwestern University, Chicago, IL, USA.
Aditi ThakurDepartment of Neurological Surgery, Northwestern University, Chicago, IL, USA.
Dolores HambardzumyanDepartment of Pediatrics, The Tisch Cancer Institute, Mount Sinai Icahn School of Medicine, New York, NY, USA.
Catalina Lee-ChangDepartment of Neurological Surgery, Northwestern University, Chicago, IL, USA.
Lara LeoniDeparment of Radiology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Craig M HorbinskiDepartment of Neurological Surgery, Northwestern University, Chicago, IL, USA.
Dmitri SimbergDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA.
Bin ZhangDepartment of Medicine, Hematology/Oncology Division, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.ORCID http://orcid.org/0000-0002-6631-7647
Amy B HeimbergerDepartment of Neurological Surgery, Northwestern University, Chicago, IL, USA.ORCID http://orcid.org/0000-0002-9970-8695
Jason MiskaDepartment of Neurological Surgery, Northwestern University, Chicago, IL, USA.ORCID http://orcid.org/0000-0001-9608-2810
Irina V BalyasnikovaDepartment of Neurological Surgery, Northwestern University, Chicago, IL, USA irinabal@northwestern.edu.ORCID http://orcid.org/0000-0002-4664-9441

Funding

Tumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Devalingam Mahalingam · 1993 to 2026
$153.9M
Fluorescent Indocarbocyanine PEGylated Lipid Nanoparticles for Understanding and Overcoming Barriers to Drug Delivery in Invasive GlioblastomaR01CA257958 · NCI · UNIVERSITY OF COLORADO DENVER · PI Irina V Balyasnikova, Dmitri Simberg · 2022 to 2026
$2.7M
Genetic Approaches to Optimize CAR T cells for Glioblastoma TherapyR01NS106379 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BALYASNIKOVA, IRINA V, GOTTSCHALK, STEPHEN · 2018 to 2022
$2.7M
Development of B-cell-based vaccine for GlioblastomaR37CA258426 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Catalina Lee Chang · 2021 to 2026
$2.2M
Understanding the Behavior of Novel IL13Ralpha2-directed T cell Engager for GBMR01NS122395 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BALYASNIKOVA, IRINA V · 2021 to 2025
$1.9M
State-of-the-art High Field 7T MRI System Upgrade to Accelerate Translational SciencesS10OD032221 · OD · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MARKL, MICHAEL · 2023 to 2023
$1.5M
Neural Stem Cell Carriers for Glioblastoma ImmunotherapyR21NS101150 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BALYASNIKOVA, IRINA V · 2017 to 2018
$775k
Neural Stem Cell Carriers for Glioblastoma ImmunotherapyR33NS101150 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BALYASNIKOVA, IRINA V · 2019 to 2019
$395k
NCI NIH HHS P30 CA060553NCI NIH HHS R01 CA257958NCI NIH HHS R37 CA258426NIH HHS S10 OD032221NINDS NIH HHS R01 NS106379NINDS NIH HHS R01 NS122395NINDS NIH HHS R21 NS101150NINDS NIH HHS R33 NS101150
6 · The paper itself

Abstract

backgroundBispecific T cell-engagers (BTEs) are engineered antibodies that redirect T cells to target antigen-expressing tumors. BTEs targeting tumor-specific antigens such as interleukin 13 receptor alpha 2 (IL13RA2) and epidermal growth factor receptor variant III (EGFRvIII) have been developed for glioblastoma (GBM). However, there is limited mechanistic understanding of the action of BTE since prior studies were mostly conducted in immunocompromised animal models. To close this gap, the function of BTEs was assessed in the immunosuppressive tumor microenvironment (TME) of orthotopic and genetically engineered mouse models (GEMM) with intact immune systems.

methodsA BTE that bridges CD3 epsilon on murine T cells to IL13RA2-positive GBM cells was developed, and the therapeutic mechanism was investigated in immunocompetent mouse models of GBM. Multicolor flow cytometry, single-cell RNA sequencing (scRNA-seq), multiplex immunofluorescence, and multiparametric MRI across multiple preclinical models of GBM were used to evaluate the mechanism of action and response.

resultsBTE-mediated interactions between murine T cells and GBM cells triggered T cell activation and antigen-dependent killing of GBM cells. BTE treatment significantly extended the survival of mice bearing IL13RA2-expressing orthotopic glioma and de novo forming GBM in the GEMM. Quantified parametric MRI validated the survival data, showing a reduction in glioma volume and decreased glioma viability. Flow cytometric and scRNA-seq analyses of the TME revealed robust increases in activated and memory T cells and decreases in immunosuppressive myeloid cells within the brains of mice following BTE treatment.

conclusionsOur data demonstrate that the survival benefits of BTEs in preclinical models of glioma are due to the ability to engage the host immune system in direct killing, induction of immunological memory, and modulation of the TME. These findings provide a deeper insight into the mechanism of BTE actions in GBM.

Indexed as

Antibodies, BispecificBrain NeoplasmsGlioblastomaGliomaImmunologic MemoryT-LymphocytesTumor MicroenvironmentAnimalsCell Line, TumorDisease Models, AnimalFemaleHumansMiceAntibodies, BispecificBispecific T cell engager - BiTEImmunotherapySolid tumor

Identifiers

PMID41151835
PMCPMC12570949

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.